Roivant Sciences/ROIV

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Ticker

ROIV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

London, United Kingdom

Employees

908

Roivant Sciences Metrics

BasicAdvanced
$7.8B
Market cap
2.02
P/E ratio
$5.23
EPS
1.25
Beta
-
Dividend rate
$7.8B
1.25
25.236
24.811
7.41
7.75
-31.05%
-14.04%
105.04%
2.02
66.28
1.43
1.46
-10.79
103.65%
-468.50%
73.74%
59.69%

What the Analysts think about Roivant Sciences

Analyst Ratings

Majority rating from 11 analysts.
Buy

Roivant Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-522.83% profit margin
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$29M
-22.10%
Net income
-$151M
-102.97%
Profit margin
-522.83%
-103.81%

Roivant Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 37.36%
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.38
-$0.40
$6.03
-$0.19
-
Expected
-$0.30
-$0.31
-$0.32
-$0.30
-$0.29
Surprise
27.69%
29.63%
-1,984.38%
-37.36%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Roivant Sciences stock?

Roivant Sciences (ROIV) has a market cap of $7.8B as of July 04, 2024.

What is the P/E ratio for Roivant Sciences stock?

The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 2.02 as of July 04, 2024.

Does Roivant Sciences stock pay dividends?

No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Roivant Sciences dividend payment date?

Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.

What is the beta indicator for Roivant Sciences?

Roivant Sciences (ROIV) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Roivant Sciences stock

Buy or sell Roivant Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing